---
title: Reduce motor and nonmotor symptoms
nct_id: NCT06548256
phase: NA
status: RECRUITING
sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06548256"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06548256"
last_fetched: "2026-05-10T14:08:37.445Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce motor and nonmotor symptoms

**Goal (in five words):** Reduce motor and nonmotor symptoms

**Official Title:** The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease

**Trial ID:** [NCT06548256](https://clinicaltrials.gov/study/NCT06548256)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Target Enrollment:** 400 participants
- **Start Date:** 2023-10-31
- **Completion Date:** 2026-12-31
- **Conditions:** Clostridium Butyricum Miyairi, Parkinson Disease
- **Interventions:** Miyarisan-BM (Clostridium Butyricum Miyairi)
- **Intervention Types:** DRUG

## Summary For Families

The trial is testing whether the probiotic Clostridium butyricum Miyairisan can help improve motor and non-motor Parkinson's symptoms, especially gut-related problems that can worsen medication response. Miyarisan-BM is a live probiotic that produces butyrate and helps rebalance the gut microbiome, which may reduce intestinal inflammation, ease constipation, strengthen the gut barrier, and indirectly affect how levodopa is absorbed and how well motor symptoms are controlled. People aged 20 to 90 with Parkinson's disease can join, but those with Parkinson's disease dementia or lactose intolerance are excluded.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 90 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Male or female over 20 years old, diagnosed with Parkinson's disease.

Exclusion Criteria:

* People with Parkinson's disease Dementia, or Lactose Intolerance
```

## Locations (1)

- Kaohsiung Medical Univeristy Hospital, Kaohsiung City, Taiwan _(22.6163, 120.3133)_
  - Yang-Pei Chang, M.D.; MSc, — (CONTACT) — 886-7-2911101 — cyp905@gmail.com

## Central Contacts

- Yang-Pei Chang, M.D.; MSc. — (CONTACT) — 886-7-2911101 — cyp905@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06548256*  
*HTML version: https://parkinsonspathways.com/trial/NCT06548256*  
*Source data: https://clinicaltrials.gov/study/NCT06548256*